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1. Introduction 
The last decade has seen a huge interest in the field of regenerative biology, with particular 
emphasis on the use of isolated or purified stem and progenitor cells to restore structure and 
function to damaged organs. Circulating endothelial progenitor cells (EPCs) have been 
studied as a potential cell source that contributes to neovascularization via postnatal 
vasculogenesis (Asahara et al., 1997). EPCs are reported to naturally home and integrate into 
sites of physiological vessel formation in vivo and incorporate into the vasculature of 
tumors, ischemic skeletal and cardiac muscle (Asahara et al., 1999). Furthermore, 
Accumulating evidence demonstrates a relationship between the frequency of circulating 
EPCs and cardiovascular disease risk (Hill et al., 2003). In the following, we will review the 
putative role of EPCs in endothelial repair and provides evidence for their influence on 
atherosclerosis. 
2. Identification of EPCs 
Despite the availability of effective preventive measures, coronary artery disease (CAD) 
remains a leading cause of morbidity and mortality in most industrialized countries. 
Convincing evidence indicates that the integrity and functional activity of the endothelial 
monolayer play an important role in atherogenesis. Traditional view suggests that 
endothelium integrity is maintained by neighboring mature endothelial cells which migrate 
and proliferate to restore injured endothelial cells. However, a series of clinical and basic 
studies prompted by the discovery of bone marrow-derived EPCs have provided new insights 
into these processes and demonstrate that the injured endothelial monolayer is regenerated 
partly by circulating EPCs. Putative circulating endothelial progenitors were first described in 
the adult human by Asahara et al. (Asahara et al., 1997) in 1997. They used the presence of 
CD34 to sort cells from the adult peripheral blood mononuclear component, based on the 
knowledge that this antigen is carried by both the angioblasts and haemopoietic stem cells 
responsible for vasculogenesis in embryonic life. By culturing MNCs (mononuclear cells) 
enriched or depleted in these CD34+ cells, they showed that the CD34+ component is able to 
give rise to spindle-shaped cells after 3 days, which become attached to fibronectin. Such 
culture led to an up-regulation of endothelial lineage markers such as CD31, Flk-1 and Tie2, 
and loss of the pan-leucocyte CD45 antigen, in these attaching cells. Asahara et al. (Asahara et 
www.intechopen.com
 
Traditional and Novel Risk Factors in Atherothrombosis 
 
72
al., 1999) went on to deliver labelled, CD34+-enriched, MNCs into mouse and rabbit models of 
hindlimb ischemia and demonstrated neovascularization in the relevant limb with apparent 
incorporation of labelled cells into capillary walls. In separate experiments, they delivered 
murine labelled-MNCs enriched for Flk-1 and similarly found incorporation into capillaries 
and small arteries in the mouse hindlimb ischemia model. Carriage of CD31 and lectin binding 
was observed in these incorporated cells. These landmark studies suggest that circulating 
EPCs in adult peripheral blood could differentiate into cells of endothelial lineage and enhance 
revascularization through vasculogenesis. 
3. Issues of definition for EPCs 
Since these important findings, an enormous amount of research has been undertaken into 
EPCs; however, in attempting to collate and interpret these results, a major limiting factor is 
that no simple definition of EPCs exists at the present time, and various methods to define 
EPC have been reported. This pertains to the unresolved issue of how EPCs should best be 
defined. 
3.1 Antigen-based definitions of EPC 
The first method of classification of EPC is based on expression of cell-surface antigens, 
typically using flow cytometry to quantify relevant populations. Endothelial cells (EC) 
display a characteristic combination of such antigens, including CD34, KDR (kinase insert 
domain-containing receptor, a type of VEGFR2), VE-cadherin, vWF (von Willebrand factor) 
and E-selectin. In order to distinguish mature endothelial cells from circulating endothelial 
progenitors, some groups have additionally used other antigens which are lost during 
maturation of endothelial lineage cells, most commonly CD133 (also termed AC133) 
(Hristov & Weber, 2004). The combination of CD34, KDR and CD133 has been used by 
several investigators, although many others have used only two of these three. 
Unfortunately, even with use of all three, this phenotype is not entirely specific, since this 
same cluster of antigens may also be found on haemopoietic stem cells (Adams & Scadden, 
2006; Verfaillie, 2002). This relates to the probable origin of haemopoietic and EC lines from 
a common precursor, termed the haemangioblast. As haemopoietic stem cells differentiate, 
CD34, KDR and CD133 antigens are down-regulated and disappear. Furthermore, the use of 
CD133 to make the distinction from mature ECs will also lead to the exclusion of ‘more 
mature’ EPCs which may have lost this marker, while not yet being terminally 
differentiated. To complicate matters further, while the use of antigenic combinations may 
have logical appeal, whether this approach actually identifies a group of precursors capable 
of producing ECs has recently been challenged (Case et al., 2007). 
3.2 Culture-based definitions of EPC 
The second commonly employed definition for EPCs derives from in vitro culture work. 
Asahara et al. described in vitro culture of CD34-enriched MNCs leading to the formation of 
spindle-shaped attaching cells within 3 days (Asahara et al., 1997). Co-culture of CD34-
enriched and CD34-depleted cells gave rise, within 12 hours, to multiple clusters, containing 
round cells centrally and sprouts of spindle-shaped cells at the periphery. This cluster 
appearance was reminiscent of the blood islands previously described, wherein angioblasts 
surround hematopoeitic stem cells as the initial stage of vasculogenesis (Flamme & Risau, 
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1992). Various culture preparations have been used to encourage endothelial lineage 
proliferation from human blood-derived MNCs. There has been a considerable variation in 
the details of techniques used: for example, some have replated the adherent cells after 2 
days initial culture, whereas others have used the non-adherent cells at this time (Vasa, 
2001). Then, endothelial cell lineage was confirmed by indirect immunostaining with the use 
of DiI-acLDL and co-staining with BS-1 lectin. However, controversy exists with respect to 
the identification and the origin of EPCs, which are isolated from peripheral blood 
mononuclear cells by cultivation in medium favoring endothelial differentiation. 
4. Early and Late outgrowth EPCs 
EPCs can be isolated, cultured, and differentiated ex vivo from the circulating mononuclear 
cells (MNCs) and exhibit characteristic endothelial properties and markers. Currently, two 
types of EPCs, namely early and late outgrowth EPCs, can be derived and identified from 
peripheral blood. The early EPCs appear after 3-5 days of culture, are spindle-shaped, have 
peak growth at approximately 2 weeks and die by 4 weeks. These have been variously termed 
‘early EPCs’ by Gulati et al. (Gulati et al., 2003) and Hur et al. (Hur et al., 2004), ‘attaching cells’ 
by Asahara et al. (Asahara et al., 1997) and CACs (circulating angiogenic cells) by Rehman et 
al. (Rehman et al., 2003). The second type of EPCs appears only after longer culture, of 
approximately 2-3 weeks, forming a cobblestone monolayer with near-complete confluence, 
and can show exponential population growth without senescence over 4-8 weeks and live for 
up to 12 weeks. These were termed ‘late EPCs’ by Hur et al. (Hur et al., 2004) or OECs by Lin et 
al. (Lin et al., 2000) and Gulati et al. (Gulati et al., 2003). Early and late outgrowth EPCs (OECs) 
share some endothelial phenotype similarities but show different morphology, proliferation 
rate, survival features, and functions in neovascularization. For clarity, we will use the terms 
early EPCs and OECs in the present review. 
Early EPCs, in contrast, do not participate in tube-forming assays, have only weak invasive 
ability on gels and produce only low levels of NO. They do, however, demonstrate some 
features in keeping with an endothelial lineage such as acetylated LDL uptake and lectin 
binding. In addition, early EPCs do not develop into OECs upon prolonged culture. Among 
antigenic markers, CD14 (a monocytic marker) has been found by several groups on early 
EPCs (Romagnani et al., 2005; Urbich et al., 2003). Early EPCs lack the impressive replicative 
ability of OECs, but are prolific producers of several growth factors, cytokines and 
chemokines, including VEGF, HGF (hepatocyte growth factor), G-CSF (granulocyte colony-
stimulating factor) and GM-CSF (granulocyte/macrophage colony-stimulating factor). The 
lineage origin of these two culture-derived endothelial-type cells has been examined. 
Expression of the pan-leucocyte antigen CD45 is relatively greatest in MNCs, lower in early 
EPCs and lowest in OECs. It appears that early EPCs are mostly derived from a CD14+ 
population of MNCs, implying a monocytic, rather than true endothelial, lineage (Yoon et 
al., 2005). In contrast, OECs derive exclusively, or almost exclusively, from the CD14− 
population of MNCs (Yoon et al., 2005). It has been suggested that the MNCs from which 
OECs are derived may represent a ‘true’ circulating endothelial precursor (angioblasts). 
OECs have many similarities to mature ECs, in terms of surface antigens (including KDR, 
vWF, and VE-cadherin) and high levels of NO (nitric oxide) production by eNOS 
(endothelial NO synthase). They are able to participate effectively in tube-forming assays in 
vitro. However, OECs differ from mature ECs in having far greater proliferative ability in 
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vitro and greater angiogenic potential in vivo. A small population of OECs with the highest 
proliferative potential was able to produce more than 200 progeny per replated cell. Based 
on these findings, these features make OECs attractive candidates for therapeutic use in 
ischemia-related neovascularization. 
5. Endothelial progenitor cells and atherosclerosis 
The discovery of endothelial progenitors within adult peripheral blood presents another 
possible means of vascular maintenance, namely a reservoir of circulating cells which can 
home to sites of injury and restore endothelial integrity thus allowing continued normal 
function. Hill et al. (Hill et al., 2003) studied men without known cardiovascular disease but 
with varying degrees of estimated cardiovascular risk. Endothelial function was determined 
by using brachial artery flow-mediated vasodilation, and EPC numbers were measured 
using their CFU assay in study subjects. An inverse correlation was found between numbers 
of CFUs and the overall Framingham risk score of the participants. Furthermore, they found 
a positive correlation between the number of EPCs and endothelial function as assessed by 
brachial artery reactivity of the subjects. These findings are compatible with the hypothesis 
that an adequate pool of EPCs in the blood may be a key requirement for appropriate 
endothelial function. It appears that bone marrow-derived EPCs play a pivotal role in the 
maintenance of adult vascular endothelium. However, the basis of this correlation between 
EPC levels and endothelial function remains to be determined. 
Although the critical role of circulating EPCs in the pathogenesis of atherosclerotic 
diseases is substantiated by several observations, the relationship between circulating 
EPCs and coronary artery disease (CAD) remains a subject of debate. Several studies have 
examined the association between circulating EPCs and CAD or risk factors predisposing 
to coronary artery disease. Vasa et al. reported that the circulating EPCs levels were 
significantly reduced in patients with CAD compared to those without CAD (Vasa et al., 
2001). Wang and coworkers indicated that decreased number and activity of EPCs were 
observed in patients with stable CAD, and EPC levels were negatively correlated with the 
severity of coronary stenosis assessed by Gensini score (Wang et al., 2007). Fadini et al. 
also reported that EPCs were significantly reduced in subjects with increased intima-
media thickness (Fadini et al., 2006), implying that depletion of EPCs may be an 
independent predictor of subclinical atherosclerosis. However, Guven et al. showed that 
increased EPCs levels were associated with the presence of significant CAD, and EPC 
numbers correlated with maximum angiographic stenosis severity (Guven et al., 2006). 
The apparent conflicting results between different studies may have many explanations, 
including fundamental differences in the methodologies used to identify circulating EPCs 
in different studies; heterogeneity of patient population, and effect of the disease stage on 
biological properties of circulating EPC levels. Based on the angiographic classifications 
by Syntax score, our recent work has shown that severe CAD patients (with higher Syntax 
Score) have decreased circulating EPCs numbers than mild CAD patients and subjects 
with normal angiographic results (unpublished data). Moreover, circulating EPC levels 
were shown to be negatively correlated with the SXscore in patients with angiographic 
evidence of CAD. These findings are consistent with a recent study showing that lower 
level of circulating EPCs predicts CAD progression (Briguori et al., 2010), suggesting the 
critical role of EPCs in the pathogenesis of CAD.  
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6. Anti-atherosclerotic actions of EPC 
Rapid and complete restoration of endothelial integrity and function prevents development 
and growth of a neointimal lesion; however, inadequate response to injury will instead 
allow the formation of an atheromatous lesion. The discovery of circulating endothelial 
progenitors has led to the theory that they are important mediators of this repair arm, and 
hence that a depletion or dysfunction in these cells would result in an imbalance between 
endothelial injury and repair, favoring atherosclerosis. Schmidt-Lucke et al. (Schmidt-Lucke 
et al., 2005) followed up a group of 120 individuals, comprising normal subjects and also 
patients with either stable or unstable coronary artery disease. They found that major 
cardiovascular events, CABG (coronary artery bypass grafting) or ischemic stroke were 
significantly more frequent in the subgroup with lower levels of circulating CD34/KDR 
double-positive cells at baseline. This association persisted after accounting for conventional 
cardiovascular risk factors. Werner et al. (Werner et al., 2005) studied CD34/KDR double-
positive cell numbers in a cohort of 519 patients diagnosed with coronary artery disease by 
angiography. After adjustment for confounding variables, higher levels of EPCs were 
associated with a reduced risk of death from cardiovascular causes and of occurrence of a 
first cardiovascular event at 12 months follow-up. The authors followed up the outcomes 
when patients were grouped by baseline levels of CFUs (i.e. a culture-based definition of 
colony formation). Higher CFU formation was associated with a reduced occurrence of a 
first major cardiovascular event and reduced revascularization at follow-up. However, as 
discussed above, recent work on the CFU assay suggests that it is assessing the in vitro 
activity of cells which may be relevant to vascular function, but which are not actually EPCs 
themselves (Rohde et al., 2007; Hur et al., 2007). 
Moreover, there is relevant animal-based work in this area of progenitor cells and 
endothelial function. Wassmann et al. (Wassmann et al., 2006) studied endothelial function 
in ApoE-knockout mice, on a high-cholesterol diet, with atherosclerotic plaques and 
demonstrable endothelial dysfunction of aortic rings ex vivo. They showed that the 
intravenous administration of spleen-derived MNCs improved endothelium-dependent 
vasodilation. In addition, Gulati et al. (Gulati et al., 2003). used a rabbit model of balloon 
injury to the carotid arteries. They cultured peripheral blood MNCs in endothelial growth 
medium for 2 weeks, producing endothelial-phenotype cells carrying CD31 and eNOS, and 
delivered these culture-modified cells immediately after balloon injury. They found that, 
compared with saline-treated controls, local treatment with EPCs led to accelerated re-
endothelialization and improved endothelial function. Whether the improvement in 
endothelial function is directly due to increased numbers of new ECs or an indirect effect on 
pre-existing cells or a papacrine effect by implantation of EPCs remains unclear; however, 
an increase in vascular NOS activity was documented and is likely to mediate the effect. 
7. Therapeutic implications and perspective 
A crucial target in the treatment or prevention of atherosclerosis is to promote and maintain 
the integrity and health of endothelium. Since EPCs play a role in maintaining an intact and 
functional endothelium, decreased and dysfunctional EPCs may contribute to endothelial 
dysfunction and susceptibility to atherosclerosis. Enhancement of the regenerative capacity 
of the injured endothelium seems one way to reduce the incidence of atherosclerotic lesions 
(Hristov & Weber, 2007). Transplantation of human cord blood-derived EPCs was reported 
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to contribute to neovascularization in various ischemic diseases, and EPC transplantation on 
diabetic wounds has a beneficial effect, mainly achieved by their direct paracrine action on 
keratinocytes, fibroblasts, and endothelial cells, rather than through their physical 
engraftment into host tissues (vasculogenesis). In the TOPCARE-AMI (i.e., “Transplantation 
of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction”) trial 
(Assmus et al., 2002), intracoronary infusion of cultured human EPCs in patients with recent 
myocardial infarction was associated with improvements in global left ventricular function 
and microvascular function. In addition, an EPC-conditioned medium was shown to be 
therapeutically equivalent to EPCs, at least for the treatment of diabetic dermal wounds 
(Kim et al., 2010). 
There are several ways to increase levels of circulating EPCs and improve their function 
by pharmacological strategies and lifestyle modification. Notably, it was shown that the 
angiotensin-converting enzyme (ACE) inhibitors such as ramipril (Min et al., 2004), and 
angiotensin II (AT II) inhibitors, like valsartan (Bahlmann et al., 2005) increased EPC 
levels in patients, probably interfering with the CD26/dipeptidylpeptidase IV system. 
Our recent data showed that moderate intake of red wine significantly enhanced 
circulating EPC levels and improved EPC functions by modifying NO bioavailability 
(Huang et al., 2010). Other studies indicated that either the phosphatidylinositol 3-
kinase/Akt/endothelial nitric oxide synthase/NO (PI3K/Akt/eNOS/NO) signaling 
pathway or the interaction between hyperglycemia and hyperlipidemia in diabetic 
patients who have vascular diseases, are potential therapeutic targets for abolishing the 
impaired function of EPCs (Wang et al., 2011). Neutralization of the p66ShcAgene, which 
regulates the apoptotic response to oxidative stress, prevented high glucose-induced EPC 
impairment in vitro (Di et al., 2009). The existence of molecules acting on EPCs can be 
used to positively condition cultured EPCs before therapeutic transplantation. Thus, 
because it is known that chemokine SDF-1α is able to mobilize EPCs, and because EPCs 
are known to have receptors for SDF-1α, it was demonstrated that SDF-1α - primed EPCs 
exhibit increased adhesion to HUVEC, resulting in more efficient incorporation of EPCs 
into sites of neovascularization (Zemani et al., 2008).  
8. Conclusions 
In conclusion, EPCs are biomarkers of endothelial repair with therapeutic potential, since 
low EPC levels predict endothelial dysfunction and a poor clinical outcome. Various studies 
have focused on the important role of EPCs in vasculogenesis and angiogenesis of ischemic 
tissue in peripheral artery disease as well as acute myocardial infarction, but only a few 
studies have concentrated on the role of EPCs in the prevention and therapy of 
atherosclerosis.  
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